We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




High-Resolution Cancer Virus Imaging Uncovers Potential Therapeutic Targets

By LabMedica International staff writers
Posted on 17 Feb 2026

Human T-cell leukemia virus (HTLV) is a retrovirus that causes adult T-cell leukemia/lymphoma, a serious blood cancer with no approved treatment. More...

Although related to HIV, HTLV remains less understood at the molecular level, limiting the development of targeted therapies. Understanding how the virus assembles and spreads is critical for designing effective antiviral strategies. Now, new research provides high-resolution structural insights into the virus, revealing potential targets for future treatment development.

In a study led by the University of Minnesota School of Dentistry and Masonic Cancer Center (Minneapolis, MN, USA), in collaboration with the Institute for Molecular Virology (Minneapolis, MN, USA), researchers used cryogenic transmission electron microscopy and tomography to examine the HTLV capsid protein. Cryo-EM/ET enables detailed three-dimensional imaging by rapidly freezing viral samples at extremely low temperatures. The capsid protein, which forms the protective shell around the virus’s genetic material, plays a central role in viral assembly and represents a promising therapeutic target.

Using cryo-EM/ET, researchers successfully visualized the capsid protein’s structure and identified key features of viral assembly. For the first time, they measured the spatial relationship between the capsid protein and the virus’s outer layer, providing insight into capsid distribution within viral particles. The team also discovered that a negatively charged molecule known to assist HIV particle formation can interact with HTLV but is not required for its assembly. The findings, published in Nature Communications, highlight structural differences that could inform targeted drug design.

The detailed structural maps may support structure-based drug development strategies similar to those successfully used in HIV therapy. By clarifying how the capsid protein contributes to viral assembly and infectivity, the research offers a foundation for identifying compounds that disrupt this process. Future work will focus on understanding how HTLV spreads through direct cell-to-cell contact and determining how antiviral agents could interfere with capsid formation and viral replication.

“These high-resolution images will be useful for helping us understand why HTLV infectivity is strongly correlated with being associated with cells, where virus spread occurs through direct cell-to-cell contact,” said Louis Mansky, co-lead investigator of the study. “This remains a long-standing question in the field and could help guide the design of treatments for HTLV infection — a highly important task, knowing there are currently no such approved therapeutics.”

Related Links:
University of Minnesota School of Dentistry
Institute for Molecular Virology


Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.